Publications

Comparative Study
Journal Article Research Support, Non-U.S. Gov't
Ppublish 38 citations
Electronic publication date
March 17, 2010

View on Pubmed.gov 19901851 | View on doi.org 10.1097/JTO.0b0...

Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer.

Search for publications in this journal J Thorac Oncol - 5(1):10-6

  • Kyong-Ah Yoon

    Search for this expert
    1
  • Hye Jin Gil
  • Jihye Han

    Search for this expert
  • Jaehee Park

    Search for this expert
  • Jin Soo Lee

    Search for this expert

Abstract

INTRODUCTION

Polycomb group (PcG) proteins play essential roles in cellular memory systems and as cell cycle regulators by maintaining homeotic genes in their silenced states. EZH1 and EZH2, the human homologues of the Drosophila gene Enhancer of Zeste (E(z)), are defined as PcG proteins and contain a highly conserved motif, called the SET (Su(var)3-9, Enhancer of Zeste, Trithorax) domain, which is required for histone methyltransferase activity. Increased expression of the transcriptional repressor EZH2 has been reported to be associated with poor prognosis in various malignancies including breast cancer and prostate cancer. Altered expression of EZH2 was also demonstrated in lung cancer, suggesting an involvement in the progression of lung cancer.

METHODS

All 41 polymorphisms in EZH2 were genotyped in 335 patients with lung cancer and 335 age- and gender-matched healthy controls. Finally, 26 polymorphisms were selected for the statistical analysis based on minor allele frequency (>0.05) and linkage disequilibrium.

RESULTS

Two polymorphisms of EZH2, rs6950683 and rs3757441, showed a statistically significant association with reduced risk of lung cancer (adjusted OR [aOR] = 0.71, p = 0.007; aOR = 0.73, p = 0.015, respectively). Two copies of a haplotype (Ht2) of EZH2 also showed a significant association with reduced lung cancer risk (aOR = 0.45, 95% confidence interval = 0.23-0.87).

CONCLUSION

This is the first study to show a significant association between polymorphisms of the PcG gene EZH2 and lung cancer risk. This study suggests a correlation between the genotype variants in EZH2 and reduced lung cancer risk and hence presents a possible marker for lung cancer susceptibility.

References

No references provided.

Cited by 38 citations (total)

Journal Article

The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer.

Electronic publication date January 1, 2011

Search for publications in this journal Cancers (Basel)

Kenneth J O'Byrne [...] Steven G Gray et al.

Non-small cell lung cancer (NSCLC) is the most common cause of cancer related death in the world. Cisplatin and carboplatin...

Journal Article Review

Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.

Electronic publication date February 22, 2018

Search for publications in this journal Oncotarget

Anthos Christofides [...] Vassiliki A Boussiotis et al.

Polycomb group proteins regulate chromatin structure and have an important regulatory role on gene expression in various cell types. Two...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances